Premium Content

Switzer Report

Switzer Report leverages Australia's most experienced finance and markets team to provide more in-depth commentary and analysis that can benefit your portfolio. Take a free trial for yourself to find out.

Start Your Free Trial

Expert Stock Picks

Curated recommendations from our analysts

Model Portfolios

Follow our proven investment strategies

In-Depth Analysis

Detailed research on markets & sectors

The Latest from Switzer

Soul Patts is worth considering
Switzer Report Subscriber Exclusive
Investing

Soul Patts is worth considering

A 25-year record of rising dividends and market-beating returns makes Washington H. Soul Pattinson a company worth considering – but after a strong rally since…

Paul Rickard 21 Sep
HOT stock: James Hardie Industries (JHX)
Switzer Report Subscriber Exclusive
Investing

HOT stock: James Hardie Industries (JHX)

This week’s Hot Stock is James Hardie Industries, with Morgans’ Raymond Chan explaining why his research team has upgraded JHX to Accumulate following the company’s…

Maureen Jordan 21 Sep
Four ASX biotechs racing to crack the blood-brain barrier
Switzer Report Subscriber Exclusive
Investing

Four ASX biotechs racing to crack the blood-brain barrier

Getting drugs past the brain’s own security system is one of biotech’s toughest problems. I’ve found four ASX-listed companies – Telix, Noxopharm, Neurizon and Ceretas…

James Dunn 21 Sep
Buy, Hold, Sell, What the Brokers Say (21 September 2026)
Switzer Report Subscriber Exclusive
Investing

Buy, Hold, Sell, What the Brokers Say (21 September 2026)

Let’s run through the week’s ratings changes from the seven brokers monitored daily by FNArena, including a swathe of upgrades led by Lovisa Holdings, a…

Rudi Filapek-Vandyck 21 Sep

Join our newsletter community

Get the latest financial, business, and political expert commentary delivered to your inbox every weekday.

Investing

View All